

Tomonori Nakazato

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8894477/publications.pdf>

Version: 2024-02-01

37
papers

267
citations

933447

10
h-index

1058476

14
g-index

37
all docs

37
docs citations

37
times ranked

394
citing authors

#	ARTICLE	IF	CITATIONS
1	Cytomegalovirus reactivation with bendamustine in patients with low-grade B-cell lymphoma. <i>Annals of Hematology</i> , 2015, 94, 515-517.	1.8	20
2	Refractory Plasmablastic Type Myeloma with Multiple Extramedullary Plasmacytomas and Massive Myelomatous Effusion: Remarkable Response with a Combination of Thalidomide and Dexamethasone. <i>Internal Medicine</i> , 2009, 48, 1827-1832.	0.7	18
3	<i>Pneumocystis jirovecii</i> pneumonia detected by FDG-PET. <i>Annals of Hematology</i> , 2010, 89, 839-840.	1.8	18
4	Clinical characteristics of methotrexate-associated lymphoproliferative disorders: relationship between absolute lymphocyte count recovery and spontaneous regression. <i>Rheumatology International</i> , 2017, 37, 1629-1633.	3.0	17
5	The prognostic value of the controlling nutritional status score in patients with multiple myeloma. <i>Leukemia and Lymphoma</i> , 2020, 61, 1894-1900.	1.3	16
6	Cytomegalovirus reactivation in patients with multiple myeloma. <i>European Journal of Haematology</i> , 2016, 96, 78-82.	2.2	15
7	PET-negative pulmonary intravascular large B cell lymphoma diagnosed by a random transbronchial lung biopsy. <i>Annals of Hematology</i> , 2012, 91, 811-812.	1.8	14
8	Lenalidomide is active for extramedullary disease in refractory multiple myeloma. <i>Annals of Hematology</i> , 2012, 91, 473-474.	1.8	13
9	The prognostic value of positron emission tomography/computed tomography in rheumatoid arthritis patients with methotrexate-associated lymphoproliferative disorders. <i>Annals of Hematology</i> , 2018, 97, 1611-1618.	1.8	12
10	Importance of Histologic Verification of Positive Positron Emission Tomography/Computed Tomography Findings in the Follow-Up of Patients With Malignant Lymphoma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2015, 15, 753-760.	0.4	11
11	Lenalidomide Is Effective for the Treatment of Bortezomib-Resistant Extramedullary Disease in Patients With Multiple Myeloma: Report of 2 Cases. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2013, 13, 83-85.	0.4	9
12	Brentuximab vedotin is effective for rheumatoid arthritis in a patient with relapsed methotrexate-associated Hodgkin lymphoma. <i>Annals of Hematology</i> , 2018, 97, 1489-1491.	1.8	9
13	The prognostic value of the controlling nutritional status score in patients with myelodysplastic syndrome and acute myeloid leukemia with myelodysplasia related changes treated with azacitidine. <i>Leukemia and Lymphoma</i> , 2020, 61, 2995-2997.	1.3	9
14	Introduction of second-generation tyrosine kinase inhibitors may reduce the prognostic impact of high-risk patients, according to the European treatment and outcome study (EUTOS) score. <i>Leukemia and Lymphoma</i> , 2018, 59, 1105-1112.	1.3	8
15	Comparison of R-CVP with R-CHOP for very elderly patients aged 80 or over with diffuse large B cell lymphoma. <i>Annals of Hematology</i> , 2017, 96, 1225-1226.	1.8	6
16	Incidence and outcome of second malignancies in patients with chronic myeloid leukemia during treatment with tyrosine kinase inhibitors. <i>Medical Oncology</i> , 2018, 35, 99.	2.5	6
17	The prognostic value of geriatric nutritional risk index in patients with follicular lymphoma. <i>Annals of Hematology</i> , 2019, 98, 1777-1779.	1.8	6
18	Prognostic Impact of ABO Blood Group on Survival in Patients With Malignant Lymphoma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2020, 20, 122-129.	0.4	6

#	ARTICLE	IF	CITATIONS
19	The clinical significance of the prognostic nutritional index in very elderly patients over 80 years of age with diffuse large B-cell lymphoma. <i>Annals of Hematology</i> , 2020, 99, 1153-1155.	1.8	6
20	ATL-like marked atypical lymphocytosis associated with drug-induced hypersensitivity syndrome and human herpesvirus-6 reactivation. <i>International Journal of Hematology</i> , 2009, 90, 648-650.	1.6	5
21	Sustained complete remission in an elderly patient with a blastic plasmacytoid dendritic cell neoplasm following autologous peripheral blood stem cell transplantation. <i>Annals of Hematology</i> , 2013, 92, 1285-1286.	1.8	5
22	Successful treatment of eltrombopag-resistant refractory immune thrombocytopenia with romiplostim. <i>International Journal of Hematology</i> , 2013, 97, 291-293.	1.6	5
23	A rare case of an acquired factor V inhibitor in a patient with myelodysplastic syndrome during azacitidine treatment. <i>Annals of Hematology</i> , 2018, 97, 2009-2010.	1.8	5
24	Successful treatment with ponatinib for central nervous system relapse of Philadelphia chromosome-positive B-cell acute lymphoblastic leukaemia. <i>Internal Medicine Journal</i> , 2019, 49, 1332-1334.	0.8	5
25	The geriatric nutritional risk index predicts the early death and survival in patients with myelodysplastic syndrome and acute myeloid leukemia with myelodysplasia-related changes treated with azacitidine. <i>Hematological Oncology</i> , 2020, 38, 611-613.	1.7	4
26	The prognostic value of the Fibrinogen-Albumin Ratio Index in patients with myelodysplastic syndrome and acute myeloid leukemia with myelodysplasia-related changes treated with azacitidine. <i>Annals of Hematology</i> , 2021, 100, 953-957.	1.8	3
27	Intravenous busulfan-induced reversible leukoencephalopathy syndrome. <i>Annals of Hematology</i> , 2011, 90, 1491-1492.	1.8	2
28	Association between a cardiovascular disease risk assessment and the molecular response to tyrosine kinase inhibitors in chronic-phase chronic myeloid leukemia patients. <i>Medical Oncology</i> , 2017, 34, 66.	2.5	2
29	Rare case of ocular adnexal relapse with mantle cell lymphoma treated with ibrutinib monotherapy. <i>Internal Medicine Journal</i> , 2019, 49, 1187-1189.	0.8	2
30	Prognostic significance of hyperfibrinogenemia in patients with lower-risk myelodysplastic syndromes. <i>Annals of Hematology</i> , 2020, 99, 189-191.	1.8	2
31	Prognostic significance of the modified Barthel index in elderly patients with diffuse large B-cell lymphoma. <i>European Journal of Internal Medicine</i> , 2020, 75, 110-111.	2.2	2
32	Phase II clinical trial of personalized VCD-VTD sequential therapy using the Vulnerable Elders Survey-13 (VES-13) for transplant-ineligible patients with newly diagnosed multiple myeloma. <i>Annals of Hematology</i> , 2021, 100, 2745-2754.	1.8	2
33	Outcomes of adolescents and young adults with chronic-phase chronic myeloid leukaemia treated with tyrosine kinase inhibitors. <i>Annals of Medicine</i> , 2022, 54, 1244-1254.	3.8	2
34	Primary Bone Lymphoma of the Scapula. <i>Internal Medicine</i> , 2009, 48, 2157-2158.	0.7	1
35	The prognostic value of circulating myeloblasts in patients with myelodysplastic syndromes treated with azacitidine. <i>Medical Oncology</i> , 2019, 36, 25.	2.5	1
36	Urachal remnant infection leading to <i>Pseudomonas aeruginosa</i> bacteremia in induction therapy for adult B-cell acute lymphoblastic leukemia. <i>International Journal of Hematology</i> , 2011, 94, 298-299.	1.6	0

#	ARTICLE	IF	CITATIONS
37	The Prognostic Significance of Pretransplant Plasma Fibrinogen Levels in Autologous Hematopoietic Stem Cell Transplantation. Transplantation Proceedings, 2021, 53, 405-407.	0.6	0